Edition:
Deutschland

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

13.81USD
3 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$13.81
Open
$13.71
Day's High
$14.07
Day's Low
$13.61
Volume
250,271
Avg. Vol
279,153
52-wk High
$15.60
52-wk Low
$7.58

Innoviva, Inc., formerly Theravance, Inc., incorporated on November 19, 1996, focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. The Company is also entitled to approximately 15% of any future payments made by GSK under its agreements originally entered into with it, and since assigned to Theravance Respiratory Company, LLC (TRC). RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Company Address

Innoviva Inc

2000 Sierra Point Pkwy Ste 500
BRISBANE   CA   94005-1830
P: +1650.2389600
F: +1302.6555049

Company Web Links

Officers & Directors

Name Age Since Current Position

Odysseas Kostas

45 2018 Independent Chairman of the Board

Pavel Raifeld

2020 Chief Executive Officer

Marianne Zhen

51 2018 Chief Accounting Officer

George Bickerstaff

64 2017 Independent Director

Mark DiPaolo

49 2018 Independent Director